English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Tetragonal  (t)- LaVO 4  has turned out to be a potential host for luminescent materials. Synthesis of  t- LaVO 4  till date has been based on chelating effect of EDTA making it not ideal for bioimaging applications. An alternative was proposed by us through the use of catechin. In recent times there is interest for new MRI contrast agents that can through appropriate doping function both as MRI contrast and optical/upconversion materials. It is generally believed that under appropriate doping,  t- LaVO 4  would be a better upconversion material than monoclinic ( m)- LaVO 4 . Based on these postulations, this work explores the use of gadolinium doped  t- LaVO 4  as an MRI contrast agent. From literature, gadolinium oxide is a good T 1  contrast agent. Through this work, using catechin as a template for the synthesis of Gd doped  t- LaVO 4 , we demonstrate the possible use as a T 1  contrast agent. Interestingly, as the catechin concentration changes, morphology changes from nanorods to square nanoplates and spheres. In this process, a switch from T 1  to T 2  contrast agent was also observed. Under optimal concentration of catechin, with a rod shaped Gd doped  t- LaVO 4  an r 2 /r 1  value of 21.30 was observed. Similarly, with a spherical shape had an r 2 /r 1  value of 1.48 was observed.

Catechin tuned magnetism of Gd-doped orthovanadate through morphology as T1-T2 MRI contrast agents